To assess SGZ predictions of tumor zygosity, we examined data from the most frequently mutated somatic variants at oncogenes (BRAF, EGFR, IDH1, KRAS, NRAS, PIK3CA) and tumor suppressor genes (TP53, RB1, PTEN) in the Foundation Medicine clinical sample set. This evidence concerns the gene EGFR and neoplasm.